On July 25, 2019, Health Canada released an updated version of the Guidance Document: The Management of Drug Submissions and Applications. The updates follow from an earlier consultation and reflect updated processes and procedures related to filing a submission or application to Health Canada. These changes include a broad reorganization of information, an added section on classification of a therapeutic product (e.g., as a drug, biologic, a medical device or a combination product), and modified times to respond to a clarification request during a scientific review, which are based on the type and performance standard of the submission/application.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More -
Ministerial Reliance Order permitting Health Canada to rely on decisions of foreign regulators now in force
On July 15, 2026, the Minister of Health’s Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs ("Reliance Order”) was pub...Read More -
Health Canada seeks feedback on pilot to prioritize domestically manufactured generic drug submissions
In a News Release dated July 15, 2026, Health Canada advised that it is modernizing its regulatory processes to improve efficiency while maintaining high standards for safety, efficacy and quality.Read More
